Approved indication: Dipentum is approved to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine.

Off-label uses: Clinicians sometimes use olsalazine to treat mild to moderate active ulcerative colitis or to maintain remission in adults regardless of sulfasalazine tolerance, but other oral mesalamine formulations are generally preferred because they cause less diarrhea; it has not shown benefit for maintaining remission in Crohn’s disease and is usually not used for that condition.

Efficacy expectations: In maintenance trials, Dipentum lowered relapse rates over about 6 months compared with placebo and had similar overall efficacy to sulfasalazine, though some patients still experience flares; when used for active disease, improvement in stool frequency and bleeding typically occurs over several weeks rather than immediately.

Comparison to similar drugs: Compared with sulfasalazine, Dipentum avoids sulfonamide-related adverse effects but causes dose-related watery diarrhea more often; compared with newer mesalamine tablets and capsules, its ability to maintain remission is comparable, but its higher rate of diarrhea and need for twice-daily dosing mean many clinicians reserve it for patients who cannot tolerate other 5‑ASA products.

Typical adult dosing: For maintenance of remission of ulcerative colitis in adults, the usual dose is 500 mg by mouth twice daily (typically two 250‑mg capsules per day, taken as one 500‑mg dose in the morning and one in the evening).

Dosing adjustments and special instructions: To reduce the risk of diarrhea, some clinicians begin with a lower dose (such as 250 mg twice daily) and increase gradually to the target dose; dosing for children has not been established and use in pediatric patients is generally not recommended outside of specialist care.

How to take: Take Dipentum with food and a full glass of water at about the same times each day, swallow the capsules whole without crushing or chewing, and maintain adequate fluid intake throughout the day.

Missed dose: If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose; if it is close to the next dose, skip the missed dose and resume your regular dosing schedule without doubling up.

Overdose: In suspected overdose (such as taking several extra doses or developing severe vomiting, diarrhea, dizziness, confusion, or other concerning symptoms), seek urgent medical care or contact Poison Control in the U.S. at 1‑800‑222‑1222, and call emergency services if the person collapses, has a seizure, or has trouble breathing.

Common side effects: The most frequent problem is watery diarrhea or loose stools (around 1 in 6 patients), often starting within the first week of therapy or after a dose increase; other common effects include abdominal pain or cramps, nausea, bloating, heartburn, headache, fatigue, rash or itching, and joint pain, which are usually mild to moderate and may improve if the dose is lowered or taken strictly with food.

Serious or rare adverse effects requiring urgent attention:

• Severe or persistent diarrhea, bloody stools, fever, or worsening abdominal pain, which may indicate a flare of colitis or an acute mesalamine intolerance reaction.
• Signs of kidney injury (decreased urination, swelling of legs or face, sudden weight gain, sharp back or flank pain) or liver problems (yellowing of the skin or eyes, dark urine, pale stools, severe fatigue, right‑upper‑abdominal pain).
• Allergic or hypersensitivity reactions such as chest pain, shortness of breath, new or worsening cough, severe rash or skin peeling, mouth ulcers, joint or muscle pain, or unexplained bruising or pallor, which can reflect myocarditis, pericarditis, pneumonitis, hepatitis, blood disorders, or severe cutaneous reactions like Stevens–Johnson syndrome or DRESS.

Warnings and precautions: Dipentum must not be used in patients with known hypersensitivity to salicylates, aminosalicylates, or any component of the product; it should be used cautiously in those with kidney or liver disease, a history of blood dyscrasias, or prior mesalamine or sulfasalazine intolerance, and kidney function should be checked before starting and periodically during treatment, with consideration of periodic liver tests and complete blood counts, especially in older adults.

Pregnancy and breastfeeding: Limited human data with mesalamine derivatives have not shown a clear increase in major birth defects, but animal studies with olsalazine show fetal toxicity at high doses, so use in pregnancy is individualized, balancing the risks of uncontrolled ulcerative colitis against potential drug risks; mesalamine and its metabolite enter breast milk in low amounts, and if a breastfed infant develops diarrhea or other concerning symptoms, clinicians may recommend changing therapy or stopping breastfeeding.

Comparative safety: Relative to sulfasalazine, Dipentum avoids sulfonamide-related issues such as some rashes, reversible sperm abnormalities, and folate depletion, but it causes dose-related watery diarrhea more often; when renal function is monitored, its overall systemic safety profile is broadly similar to other oral mesalamine products.

Reporting side effects and safety updates: Side effects should be reported to the prescribing clinician and can also be reported directly to the U.S. Food and Drug Administration through the MedWatch program (online or by calling 1‑800‑FDA‑1088), which also posts current safety alerts and recalls for prescription medicines.

Major drug interactions:

• Nephrotoxic drugs, including many nonsteroidal anti‑inflammatory drugs (NSAIDs) and certain blood pressure or transplant medicines, may increase the risk of kidney injury when used with Dipentum, so kidney function should be monitored closely.
• Thiopurine immunosuppressants (azathioprine, 6‑mercaptopurine, thioguanine) can have increased active metabolite levels and bone‑marrow toxicity when combined with olsalazine; clinicians often use lower thiopurine doses and monitor complete blood counts and liver tests frequently.
• Anticoagulants such as warfarin may have enhanced effect and bleeding risk, so international normalized ratio (INR) and prothrombin time should be checked more often and warfarin doses adjusted as needed.

Other medicines and products: Always inform your prescriber about all prescription and over‑the‑counter drugs, vitamins, and herbal supplements; antiplatelet agents, other salicylates, and anticoagulants can increase bleeding risk, and antidiarrheal agents like loperamide may be used short term under medical supervision to manage olsalazine-induced diarrhea.

Food, alcohol, and procedures: Taking Dipentum with food is recommended to reduce gastrointestinal side effects; there is no specific interaction with alcohol, but heavy drinking can worsen gastrointestinal irritation and liver stress, so moderation or avoidance is generally advised; as a salicylate derivative that is not approved in children, it is seldom relevant to routine childhood vaccination, but salicylate-containing drugs are typically avoided around varicella vaccination in children because of theoretical Reye’s syndrome risk.

Conditions and co-medications that increase risk: Extra caution is needed in patients with pre‑existing kidney or liver disease, blood dyscrasias, peptic ulcer or intestinal obstruction, or a history of mesalamine hypersensitivity, and Dipentum should not be used during pelvic radiation therapy because it markedly increases the risk of severe diarrhea.

Monitoring needs: Before starting and periodically during treatment, clinicians generally check serum creatinine and other kidney function tests, and may also monitor liver enzymes and complete blood counts, particularly in older adults, those taking thiopurines or anticoagulants, or those with significant comorbidities.

Q: What is Dipentum used for?
A: Dipentum is an oral 5‑aminosalicylate medicine used mainly to help keep ulcerative colitis in remission in adults who cannot tolerate sulfasalazine.

Q: How long does Dipentum take to start working?
A: When used for symptom control, improvement in bowel frequency, bleeding, and urgency typically appears over several weeks, but as a maintenance medicine its main benefit is preventing flares over months and years rather than providing instant relief.

Q: What should I do if I get diarrhea after starting Dipentum?
A: Because watery diarrhea is a common, dose-related side effect of olsalazine, you should contact your prescriber promptly; they may lower the dose, ensure you take it strictly with meals, add an antidiarrheal drug temporarily, or switch you to another 5‑ASA if diarrhea is severe or persistent.

Q: Is Dipentum the same as mesalamine?
A: Dipentum contains olsalazine, which is a prodrug that is converted by bacteria in the colon into mesalamine, so the active anti‑inflammatory effect is similar, but Dipentum has its own dosing schedule and tends to cause diarrhea more often than some mesalamine formulations.

Q: Can I take Dipentum if I am pregnant or breastfeeding?
A: Decisions about using Dipentum in pregnancy or while breastfeeding are individualized; clinicians weigh the risks of uncontrolled ulcerative colitis against limited but generally reassuring data on mesalamine derivatives, and if it is used during breastfeeding they may monitor the infant for diarrhea or other side effects.

Storage: Store Dipentum capsules at controlled room temperature (about 68°F to 77°F), in a dry place, tightly closed in the original container, and out of the reach of children.

Handling: Keep capsules intact, and protect them from excess heat, moisture, and light; do not use capsules that are damaged or show signs of deterioration.

Disposal: When you no longer need Dipentum or it expires, use a community drug take-back program if available, or mix the capsules (in a sealed container or bag) with an undesirable substance such as used coffee grounds or cat litter before placing in household trash; do not flush medicines down the toilet unless specifically instructed.